​

Edgewise Therapeutics (EWTX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

EWTX Stock Forecast

Edgewise Therapeutics (EWTX) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $20.00, with a high of $20.00 and a low of $20.00. This represents a 31.75% increase from the last price of $15.18.

$10 $15 $20 $25 $30 $35 High: $20 Avg: $20 Low: $20 Last Closed Price: $15.18

EWTX Stock Rating

Edgewise Therapeutics stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (77.78%), 1 Hold (11.11%), 1 Sell (11.11%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 1 1 7 Strong Sell Sell Hold Buy Strong Buy

EWTX Price Target Upside V Benchmarks

TypeNameUpside
StockEdgewise Therapeutics31.75%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-13
Avg Price Target-$20.00$40.00
Last Closing Price$15.18$15.18$15.18
Upside/Downside-31.75%163.50%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25463--13
Sep, 25462--12
Aug, 25462--12
Jul, 25452--11
Jun, 25352--10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 24, 2025Goldman Sachs$20.00$16.5920.55%31.75%
Mar 07, 2025Scotiabank$50.00$28.0178.51%229.38%
Dec 05, 2024Srikripa DevarakondaTruist Financial$50.00$31.5758.38%229.38%
Oct 11, 2024Yasmeen RahimiPiper Sandler$51.00$30.4667.43%235.97%
Sep 20, 2024Leonid TimashevRBC Capital$42.00$29.5042.37%176.68%
Sep 19, 2024Joseph SchwartzLeerink Partners$42.00$29.5042.37%176.68%
Jul 01, 2024Yasmeen RahimiPiper Sandler$48.00$18.01166.52%216.21%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 03, 2025ScotiabankOutperformSector Performdowngrade
Apr 02, 2025Piper SandlerOverweightOverweighthold
Mar 07, 2025ScotiabankOutperforminitialise
Dec 05, 2024CitigroupBuyBuyhold
Oct 11, 2024Piper SandlerOverweightOverweighthold
Sep 20, 2024RBC CapitalOutperformOutperformhold
Sep 19, 2024Leerink PartnersOutperformOutperformhold
Jul 01, 2024Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.57$-1.45----
Avg Forecast$-1.54$-1.49$-1.87$-2.23$-2.38$-1.24
High Forecast$-1.49$-1.43$-1.52$-2.00$-2.08$-1.24
Low Forecast$-1.59$-1.61$-2.25$-2.56$-2.61$-1.24
Surprise %1.95%-2.68%----

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$11.40M$78.47M$263.54M
High Forecast---$11.40M$78.47M$263.54M
Low Forecast---$11.40M$78.47M$263.54M
Surprise %------

Net Income Forecast

$-170M $-151M $-132M $-113M $-94M $-75M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-100.16M$-133.81M----
Avg Forecast$-100.16M$-96.86M$-120.08M$-145.07M$-149.67M$-78.89M
High Forecast$-95.09M$-90.97M$-96.96M$-127.29M$-132.84M$-78.89M
Low Forecast$-101.43M$-102.75M$-143.20M$-162.85M$-166.49M$-78.89M
Surprise %-38.15%----

EWTX Forecast FAQ

Is Edgewise Therapeutics stock a buy?

Edgewise Therapeutics stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 1 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Edgewise Therapeutics is a favorable investment for most analysts.

What is Edgewise Therapeutics's price target?

Edgewise Therapeutics's price target, set by 9 Wall Street analysts, averages $20 over the next 12 months. The price target range spans from $20 at the low end to $20 at the high end, suggesting a potential 31.75% change from the previous closing price of $15.18.

How does Edgewise Therapeutics stock forecast compare to its benchmarks?

Edgewise Therapeutics's stock forecast shows a 31.75% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Edgewise Therapeutics over the past three months?

  • October 2025: 30.77% Strong Buy, 46.15% Buy, 23.08% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 33.33% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 33.33% Strong Buy, 50.00% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Edgewise Therapeutics’s EPS forecast?

Edgewise Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.87, marking a 28.97% increase from the reported $-1.45 in 2024. Estimates for the following years are $-2.23 in 2026, $-2.38 in 2027, and $-1.24 in 2028.

What is Edgewise Therapeutics’s revenue forecast?

Edgewise Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $11.4M, followed by $78.47M for 2027, and $263.54M for 2028.

What is Edgewise Therapeutics’s net income forecast?

Edgewise Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-120M, representing a -10.26% decrease from the reported $-134M in 2024. Projections indicate $-145M in 2026, $-150M in 2027, and $-78.89M in 2028.